V. Tassell

发表

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Michael Thomas, Takashi Seto, Kazuhiko Nakagawa, 2013, The New England journal of medicine.

The Impact of the Ohana MANA Challenge on Native Hawaiian and Pacific Islander Children

V. Tassell, Kristine Kay, 2014 .

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.

P. Fasching, R. Greil, R. Kreienberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials.

N. Stollenwerk, K. Yoneda, K. Wilner, 2017, Clinical lung cancer.

Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET).

P. Jänne, J. Nemunaitis, J. Christensen, 2016 .

Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.

A. Bottomley, A. Shaw, T. Mok, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST

J. Blay, G. Demetri, A. Cesne, 2007 .

Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).

K. Kern, G. Romieu, J. Crown, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST.

J. Blay, G. Demetri, S. George, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.

J. Christensen, G. Shapiro, H. Hurwitz, 2015 .

7501 ORAL Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing

J. Blay, G. Demetri, A. Cesne, 2007 .

Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors

D. Potvin, K. Papadopoulos, D. Rasco, 2022, Targeted Oncology.

Institutional implementation of clinical tumor profiling on an unselected cancer population.

Marian Harris, Ethan Cerami, Frank C Kuo, 2016, JCI insight.

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

J. Blay, G. Demetri, P. Stephenson, 2009, European journal of cancer.

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

P. Jänne, M. Hidalgo, J. Christensen, 2017, Clinical Cancer Research.

A new species of Didogobius (Perciformes, Gobiidae) from the Canary Islands. American Museum novitates ; ; no. 2906.

V. Tassell, L. James, 1988 .

Complex renal cysts associated with crizotinib treatment

A. Shaw, Weiwei Tan, K. Wilner, 2015, Cancer medicine.

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

David Goldstein, Serge Leyvraz, Patrick Schöffski, 2012, Clinical Cancer Research.

In vitro model development for novel prevention measures against foodborne pathogens

V. Tassell, L. Maxwell, 2016 .

Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)

P. Jänne, K. O'Byrne, Michael Thomas, 2012 .

Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy.

J. Christensen, C. Blakely, P. Olson, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure

Patrick Schöffski, Paolo G. Casali, G. Demetri, 2008 .

Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors

D. Potvin, J. Christensen, Keunchil Park, 2022, Targeted Oncology.

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

J. Blay, A. Lluch, S. Verma, 2014, BMC Cancer.

Towards a perspective of the concept of intervention in international politics : a framework for analysis applied to American actions in the Dominican Republic in 1965

V. Tassell, G. Lane, 1971 .

Activity and safety of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: initial results from a phase II study.

J. Blay, A. Lluch, S. Verma, 2009 .

Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC).

S. Gettinger, Gregory Riely, B. Solomon, 2013 .

Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis

J. Blay, G. Demetri, A. Cesne, 2008 .

P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET: Topic: Phase II + NK

P. Jänne, D. Potvin, L. Cavanna, 2017 .

Breast cancer, early stage

M. Espié, C. Mermel, R. Gelber, 2012 .